[SHINSA]Points to Consider for Concordance Evaluation of Companion Diagnostics Using DNA Sequencers(Early Consideration)and Points to Consider for the Development of Companion Diagnostics for Drugs with Efficacy and Safety Demonstrated in Clinical Trials in Which Patients Were Enrolled Using Tests Selected by Clinical Trial Sites(Early Consideration) posted.

Pharmaceuticals and Medical Devices Agency (Japan) Version 5 imported change current

Imported from official source

This version

Version
5 of 5
Recorded
November 19, 2026 00:32
Change
Imported change
Content hash
9fe7d953a57cf7505761acfe43310601
All versions
Revision history

Officially records where a publication came from, not whether it is true. Imported records are reproduced from an organization's own official source.